DT-7012: A Highly Differentiated Anti-CCR8 Depleting Antibody for Clinical Success
- Identifying key differentiating features during drug discovery to overcome the competitive landscape of CCR8-targeted antibodies
- Validating a novel CCR8 antibody candidate with the potential for superior clinical efficacy through strategic design and translational focus
- Highlighting a real-time case study of our CCR8 program, from target validation to first-in-human dosing, illustrating the power of rational antibody design for GPCR therapeutics